ViiV releases more data supporting HIV drug Tivicay; Merck settles another Vioxx suit;

@FiercePharma: Ruling against GSK's Lovaza fish-oil pill puts hurt on competitor Amarin. Story | Follow @FiercePharma

@EricPFierce: South Africa's Aspen says manufacturing assets it is getting from GSK, Merck part of global push. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Is J&J's manufacturing any better off since it pledged to keep closer oversight? Second recall in two weeks. Report | Follow @CarlyHFierce

> ViiV Healthcare, the HIV drug company made up of GlaxoSmithKline ($GSK), Pfizer ($PFE) and Japan's Shionogi, has released preliminary data from a study that further supports the benefits of the HIV drug Tivicay, approved in August by the FDA. Release

> A $23 million settlement by Merck ($MRK) in a class action settlement over Vioxx, the pain drug it pulled from the market years ago, may allow patients who bought the drug before Oct. 1, 2004, to get a $50 settlement or reimbursement for out-of-pocket expenses. Release (PDF)

> Raptor Pharmaceutical's ($RPTP) rare-disease drug Procysbi, approved in the U.S. in May for treatment of nephropathic cystinosis, has now been approved in the EU for the same indication. Story

> A former Johnson & Johnson ($JNJ) employee in India has claimed to a court that he was the whistleblower who revealed that the company had failed to check ethylene oxide levels in some baby powder before it was released to the market. Report

>  Aurobindo Pharma has agreed to buy Andhra Pradesh-based Hyacinths Pharma for an undisclosed amount. Story

Medical Device News

@FierceMedDev: InVivo slides again as CFO bolts, spinal study pends. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Covidien projects a modest 2014, its first full year with no pharma revenue. Report | Follow @DamianFierce

@MarkHFierce: We have a new round of stories at FierceDiagnostics. Check them out | Follow @MarkHFierce

@MichaelGFierce: This week, in life sciences hiring: Ex-Bausch + Lomb CEO takes helm at Forest Labs... and more. Chutes & Ladders | Follow @MichaelGFierce

> Foundation Medicine eyes $92M in IPO. Report

> Study: Health reform law will produce major gains for some device companies. Article

> Medicare Dx test coverage gets revamp in new U.S. House bill. Item

Biotech News

@FierceBiotech: Trending now: Biotech R&D spending roars ahead as Big Pharma grimly holds the line. ICYMI yesterday | Follow @FierceBiotech

@JohnCFierce: Delcath gets a CRL, a demand for a new trial, some other hurdles, and fires its CEO. Busy day. Release | Follow @JohnCFierce

@EmilyMFierce: NIH partners with Eli Lilly, others on rare diseases. Article | Follow @EmilyMFierce

> Party drug ketamine gains steam for antidepressant use. Item

> Egalet scores up to $20M for next-gen pain drug as FDA aims to block abuse. Story

> Delcath gets FDA denial on cancer treatment and axes CEO. Article

> Visterra's engineered antibody passes preclinical test as universal flu treatment. More

And Finally....Boehringer Ingelheim has a new campaign for OTC heartburn treatment Zantac featuring Captain Zantac, which it claims is "the only current animated character in the over-the-counter (OTC) heartburn medication category."  Item

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."